GlassScriptPhysician profile
Robert Evan Reiter
NPI 1346269297
$144,532.17
in general payments reported to CMS, 2019-2025
24 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $29K · 2021: $7,942 · 2022: $16K · 2023: $46K · 2024: $16K · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $10K · Consulting Fee: $9,350 · Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,218.50 |
| Travel and Lodging | $10,026.24 |
| Consulting Fee | $9,350.00 |
| Food and Beverage | $4,110.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $82,237.70 | 2019-2024 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $13,951.76 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $10,962.41 | 2020-2024 | Pylarify |
| Janssen Scientific Affairs, LLC | $10,185.15 | 2019-2025 | Erleada |
| Pfizer INC. | $9,491.67 | 2019-2025 | |
| Astellas Pharma US INC | $6,043.81 | 2019-2023 | Xtandi |
| Myovant Sciences INC. | $3,950.00 | 2021 | |
| Angiodynamics, INC. | $2,000.00 | 2024 | Nanoknife |
| Advanced Accelerator Applications | $2,000.00 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $1,424.86 | 2019-2020 | |
| Blue Earth Diagnostics | $369.71 | 2022-2024 | |
| Intuitive Surgical, INC. | $327.48 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $309.22 | 2022-2025 | Lynparza |
| Genzyme Corporation | $286.63 | 2019 | |
| Dendreon Pharmaceuticals LLC | $172.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edap Technomed INC | $171.12 | 2022 | |
| Caris Mpi, INC. | $123.15 | 2025 | Mi Cancer Seek |
| Medtronic USA, INC. | $121.00 | 2020 | |
| Telix Pharmaceuticals | $119.83 | 2024-2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $100.64 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $91.51 | 2019-2020 | |
| Janssen Research & Development, LLC | $50.00 | 2023 | Erleada |
| Abbvie INC. | $33.98 | 2024 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.